Atul Pande Buys Shares of Immunovant, Inc. $IMVT
Key Points
- Atul Pande bought 1,500 shares of Immunovant, Inc. ($IMVT) worth $12,645.
- $IMVT last traded around $33.44.
Atul Pande, insider at Immunovant, Inc. ($IMVT), bought 1,500 shares at an average price of $8.43, for a total transaction of $12,645. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Immunovant, Inc. ($IMVT) Stock
Immunovant, Inc. Earnings
Analysts Set New Price Targets
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.